Bipolar Disorder, Schizo Affective Disorder, Schizophrenia Disorders
Conditions
Brief summary
This study aims to identify novel markers of psychosis using electroencephalography (EEG).
Interventions
OTHEREEG measure of visual processing
Non-invasive scalp EEG measure of early cortical visual processing.
Sponsors
National Institute of Mental Health (NIMH)
University of Rochester
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* All Subjects * Aged 18-65 * 20/32 visual acuity or better (using in-house optical correction, if necessary) * An ability to speak English well enough to complete study assessments and to consent to the study * Subjects with Schizophrenia-Spectrum Disorder * Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5). * Subjects with Bipolar Disorder * Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).
Exclusion criteria
* All subjects * Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following: * Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent. * Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter); * Actively intoxicated, as shown via patient self-report or staff report; * Substance use disorder in the past 3 months; * Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening); * Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation. * Being in a current manic state * Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter). * Subject has had electroconvulsive therapy (ECT) in the past 8 weeks; * Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records) * Lazy eye or squint or other known ocular pathology * Healthy Control Subjects * Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure); * Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * Case-match Control Non-ill Subjects * Any lifetime psychotic disorder (as assessed by SCID/or SSD); * Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD) * Persistent threshold psychotic symptoms * History of psychiatric hospitalization; * Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days * First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * Bipolar Subjects * Persistent threshold psychotic symptoms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean amplitude of EEG visual response | Day 1 |
Countries
United States
Contacts
Primary ContactEdmund Lalor, PhD
Outcome results
None listed